RECARDIO
Recardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of cardiovascular diseases.
RECARDIO
Industry:
Health Care Life Science Medical
Founded:
2011-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.recardio.eu
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Microsoft Exchange Online
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Employees Featured
Founder
Official Site Inspections
http://www.recardio.eu
- Host name: 246.145.214.35.bc.googleusercontent.com
- IP address: 35.214.145.246
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Recardio"
Recardio – Regenerative Cardiac
RECARDIO (REgenerative CARDIOvascular Therapy) is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located …See details»
Partnering - Recardio
RECARDIO offers an exciting partnering and collaboration opportunity for experienced global investment groups and players in cardiac health. To find out about this partnering opportunity …See details»
Careers - Recardio
As one of the promising life science companies with locations in the US and Europe, we are committed to developing the regenerative therapies of the future.See details»
Recardio - Crunchbase Company Profile & Funding
Recardio is a clinical-stage life science business focused on cardiovascular, cancer, and infectious disease medicines. The company focuses on developing regenerative therapeutic modalities that use a protein that is essential for …See details»
Recardio Completes Phase 2 Regenerative Post-Myocardial …
May 19, 2021 · Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, …See details»
Recardio GmbH - Life Sciences Directory
Recardio GmbH Back to list. Facts. Founded 2011 Staff 5 Organization type RDM biotech/pharma Region Carinthia Focus human health Profile. Similar companies in RDM biotech/pharma. …See details»
Background - recardio.eu
In 2015, there were an estimated 423 million cases of CVD and 18 million CVD deaths. Of these, 9 million were attributed to ischemic heart disease (also known as Coronary Heart Disease) …See details»
Recardio's Phase 2 Results Will Be Presented as Latebreaker at …
May 19, 2022 · Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's …See details»
Recardio's Digital Platform, CardioCare, Rolled Out in …
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it has rolled out its digital...See details»
Recardio Completes Phase 2 Regenerative Post …
May 20, 2021 · Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and …See details»
Recardio's Positive Phase 2 Results Presented as - GlobeNewswire
May 23, 2022 · Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's …See details»
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
Jun 1, 2022 · Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with …See details»
Management - recardio.eu
RECARDIO has an experienced management team with longtime and significant experience and reputation in drug development, cardiology, the biotech industry and is complemented by …See details»
Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented ...
Jun 29, 2020 · Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio's …See details»
Recardio's Positive Phase 2 Results Presented as Latebreaker
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's Phase 2 …See details»
Contact us - Recardio
RECARDIO Inc. 1 Market Str, Spear Tower, 36th 94105 San Francisco USASee details»
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
Jun 1, 2022 · Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with …See details»
BayPAT | BayPAT’s Licensee Recardio and FDA reach agreement on…
The regenerative therapy concept of Recardio with its DPP-IV inhibitor dutogliptin is subject to a licence agreement concluded in 2012 between BayPAT and Recardio and is based on an …See details»
Recardio at BIO-EUROPE 2023
Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic …See details»